Volume 31, Number 3—March 2025
CME ACTIVITY - Research
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes
Table 3
AUC0–24h and Cmax in participants with and without diabetes, by tuberculosis drug, in a study assessing efficacy and safety of 4-month rifapentine-based tuberculosis treatments in persons with diabetes at sites in 12 countries,* January 2016–October 2018†
Value | Diabetes status | No. participants | Mean | SD | p value‡ |
---|---|---|---|---|---|
AUC0–24h, μg × h/mL | |||||
Rifapentine | No | 1,565 | 572.44 | 183.8 | 0.25 |
Yes | 122 | 553.98 | 169.1 | ||
Moxifloxacin | No | 783 | 25.51 | 7.0 | 0.0001 |
Yes | 66 | 22.34 | 6.0 | ||
Rifampin | No | 770 | 53.32 | 37.5 | 0.94 |
Yes | 59 | 53.69 | 35.2 | ||
Isoniazid | No | 2,335 | 16.52 | 12.1 | 0.51 |
Yes | 181 | 15.80 | 14.5 | ||
Ethambutol | No | 1,552 | 15.93 | 3.2 | 0.0002 |
Yes | 115 | 14.89 | 2.8 | ||
Pyrazinamide | No | 2,335 | 346.14 | 91.5 | 0.48 |
Yes |
181 |
340.77 |
99.2 |
||
Cmax, μg/mL | |||||
Rifapentine | No | 1,565 | 33.10 | 8.7 | 0.17 |
Yes | 122 | 31.97 | 8.7 | ||
Moxifloxacin | No | 783 | 2.67 | 0.7 | 0.23 |
Yes | 66 | 2.55 | 0.8 | ||
Rifampin | No | 770 | 10.20 | 4.8 | 0.60 |
Yes | 59 | 10.52 | 4.5 | ||
Isoniazid | No | 2,335 | 2.83 | 0.9 | 0.25 |
Yes | 181 | 2.75 | 0.9 | ||
Ethambutol | No | 1,552 | 1.82 | 0.6 | 0.43 |
Yes | 115 | 1.87 | 0.6 | ||
Pyrazinamide | No | 2,335 | 30.34 | 7.2 | 0.008 |
Yes | 181 | 32.05 | 8.3 |
*Brazil, Haiti, India, Kenya, Malawi, Peru, South Africa, Thailand, Uganda, United States, Vietnam, and Zimbabwe. †AUC0–24h, area under the concentration time curve from 0–24 hours; Cmax, maximal plasma concentration. ‡A t-test was used to compare pharmacokinetic parameters between participants classified as having or not having diabetes at enrollment.
1Members of group listed at the end of this article.
2Members of group listed at the end of this article.
Page created: January 15, 2025
Page updated: February 24, 2025
Page reviewed: February 24, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.